Article
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.
Annals of the rheumatic diseases - 1 Nov 2007
Radstake Timothy R D J, Fransen Jaap, Toonen Erik J M, Coenen Marieke J H, Eijsbouts Agnes E, Donn Rachelle, van den Hoogen Frank H J, van Riel Piet L C M
Abstract excerpt
BACKGROUND: Macrophage migration inhibitory factor (MIF) is an inflammatory mediator associated with RA severity. In various diseases, MIF polymorphisms are associated with clinical response glucocorticoid (GC) treatment. It is unclear whether MIF polymorphisms determine GC response in rheumatoid arthritis (RA) and to other RA treatments. Therefore, the question of whether two functional variants in MIF are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.